Notice Pursuant to the National Cooperative Research and Production Act of 1993-Subcutaneous Drug Development & Delivery Consortium, Inc., 78148-78149 [2020-26626]
Download as PDF
<![CDATA[
78148
Federal Register / Vol. 85, No. 233 / Thursday, December 3, 2020 / Notices
other carriers to the National Register of
Historic Places, National Park Service,
1849 C Street NW, MS 7228,
Washington, DC 20240.
SUPPLEMENTARY INFORMATION: The
properties listed in this notice are being
considered for listing or related actions
in the National Register of Historic
Places. Nominations for their
consideration were received by the
National Park Service before November
21, 2020. Pursuant to Section 60.13 of
36 CFR part 60, comments are being
accepted concerning the significance of
the nominated properties under the
National Register criteria for evaluation.
Before including your address, phone
number, email address, or other
personal identifying information in your
comment, you should be aware that
your entire comment—including your
personal identifying information—may
be made publicly available at any time.
While you can ask us in your comment
to withhold your personal identifying
information from public review, we
cannot guarantee that we will be able to
do so.
Nominations submitted by State or
Tribal Historic Preservation Officers:
CALIFORNIA
Alameda County
Hotel Menlo, 344 13th St., Oakland,
SG100005984
COLORADO
Bent County
Boggsville (Boundary Increase), 2 mi. south
of Las Animas, east of CO 101, Las Animas
vicinity, BC100005980
Gilpin County
Frontenac and Aduddell Mine Complex,
(Mining Industry in Colorado, MPS), 0.25
mi. southwest of jct. of Church Placer and
Pewabic Mountain Rds., Russell Gulch
vicinity, MP100005981
ILLINOIS
Crawford County
Allen, Dr. Arthur W., Home, 11266 North
Trimble Rd., Robinson, SG100005966
Wayne County
United States Postal Service Roosevelt Park
Station, 1800 18th St., Detroit,
SG100005983
NEW YORK
Madison County
Oneida Community Limited Administration
Building, 181 Kenwood Ave., Oneida,
SG100005960
Washington County
Greenwich District School No. 11, 4 Ryan
Rd., Center Falls, SG100005961
NORTH CAROLINA
Granville County
Oxford Historic District (Boundary Increase
and Decrease), (Granville County MPS),
Roughly bounded by Alexander and Sunset
Aves., 3rd, Belle, Broad, Cherry, College,
Devin, Franklin, Front, Gilliam, Granville,
Henderson, Hillsboro, Lanier, Main, New
College, Raleigh, and West Sts., and Martin
Luther King Jr. Blvd., Oxford,
BC100005974
Hertford County
Winton Historic District, Roughly bounded
by west side of North King St., north of
Cross St., North Murfree, East Weaver, and
West Jordan Sts., Winton, SG100005976
Surry County
Country Club Estates Historic District,
Includes portions of Club View Dr.,
Country Club Rd., Fairway Ln., and
Greenhill Rd., Mount Airy, SG100005977
Lebanon Hill Historic District, Roughly
bounded by Howard, Mitchell, South, and
Woodruff Sts., and the Mount Airy Historic
District, Mount Airy, SG100005978
In the interest of preservation, a
SHORTENED comment period has been
requested for the following resource:
MARYLAND
Kent County
Piney Grove, 7281 Wilkins Ln., Chestertown,
SG100005962
Comment period: 3 days
A request to move has been received for
the following resource:
NORTH CAROLINA
Douglas County
Henson House, 103 North Henson Rd., Villa
Grove, SG100005967
Jersey County
Jerseyville First Presbyterian Church, 400
South State St., Jerseyville, SG100005968
khammond on DSKJM1Z7X2PROD with NOTICES
MICHIGAN
Alamance County
Menagerie Carousel, Burlington City Park,
South Main St., Burlington, MV82003420
Additional documentation has been
received for the following resources:
COLORADO
Winnebago County
Rockford Woman’s Club, 323 Park Ave.,
Rockford, SG100005971
Bent County
Boggsville (Additional Documentation),
South of Las Animas on CO 101, Las
Animas vicinity, AD86002841
MARYLAND
ILLINOIS
Frederick County
Ceres Bethel AME Church, Gapland Rd.,
approx. 2 mi. west of Burkittsville,
Burkittsville vicinity, SG100005982
Wayne County
Turney-Hall House (Additional
Documentation), 502 SE 4th St., Fairfield,
AD100002329
VerDate Sep<11>2014
19:48 Dec 02, 2020
Jkt 253001
PO 00000
Frm 00036
Fmt 4703
Sfmt 4703
Will County
Plainfield Halfway House (Additional
Documentation), 503 Main St., Plainfield,
AD80001421
NORTH CAROLINA
Granville County
Oxford Historic District (Additional
Documentation), (Granville County MPS),
Roughly bounded by College, New College,
Gilliam, Raleigh, Front, Broad, Goshen, and
Hayes Sts., Oxford, AD88000403
Authority: Section 60.13 of 36 CFR part 60.
Dated: November 24, 2024.
Sherry A. Frear,
Chief, National Register of Historic Places/
National Historic Landmarks Program.
[FR Doc. 2020–26616 Filed 12–2–20; 8:45 am]
BILLING CODE 4312–52–P
DEPARTMENT OF JUSTICE
Antitrust Division
Notice Pursuant to the National
Cooperative Research and Production
Act of 1993—Subcutaneous Drug
Development & Delivery Consortium,
Inc.
Notice is hereby given that, on
October 26, 2020, pursuant to Section
6(a) of the National Cooperative
Research and Production Act of 1993,
15 U.S.C. 4301 et seq. (‘‘the Act’’),
Subcutaneous Drug Development &
Delivery Consortium, Inc.
(‘‘Subcutaneous Drug Development &
Delivery Consortium, Inc.’’) has filed
written notifications simultaneously
with the Attorney General and the
Federal Trade Commission disclosing
(1) the identities of the parties to the
venture and (2) the nature and
objectives of the venture. The
notifications were filed for the purpose
of invoking the Act’s provisions limiting
the recovery of antitrust plaintiffs to
actual damages under specified
circumstances.
Pursuant to Section 6(b) of the Act,
the identity of the parties to the venture
are: Eli Lilly and Company,
Indianapolis, IN; Halozyme, Inc., San
Diego, CA; Bristol Myers Squibb, New
Brunswick, NJ; AstraZeneca, San
Francisco, CA; and Amgen Inc.,
Thousand Oaks, CA. The general area of
Subcutaneous Drug Development &
Delivery Consortium, Inc.’s planned
activity is (a) transform patient care and
improve patient outcomes by
identifying and addressing key gaps,
unmet needs and actionable issues in
the dynamic subcutaneous (‘‘SC’’) drug
delivery and development landscape,
including through research, publication
of industry analyses, and the
E:\FR\FM\03DEN1.SGM
03DEN1
Federal Register / Vol. 85, No. 233 / Thursday, December 3, 2020 / Notices
development of SC-related manuscripts,
models, standards and other guidance
materials (collectively, ‘‘Guidance’’); (b)
provide a venue for reviewing,
developing, maintaining and supporting
the Guidance; (c) promote the Guidance
worldwide; (d) provide for testing and
conformity assessment of
implementations in order to ensure and/
or facilitate compliance with Guidance;
(e) operate a branding program based
upon distinctive trademarks to create
high customer awareness of, demand
for, and confidence in the Guidance,
and products or services designed in
compliance therewith; and (f) undertake
such other activities as may from time
to time be appropriate to further the
purposes and achieve the goals set forth
above.
Membership in Subcutaneous Drug
Development & Delivery Consortium,
Inc. remains open and Subcutaneous
Drug Development & Delivery
Consortium, Inc. intends to file
additional written notifications
disclosing all changes in membership.
In
accordance with 21 CFR 1301.33(a), this
is notice that on November 11, 2020,
Janssen Pharmaceuticals Inc., 1440
Olympic Drive, Athens, Georgia, 30601–
1645, applied to be registered as an bulk
manufacturer of the following basic
class(es) of controlled substance(s):
SUPPLEMENTARY INFORMATION:
Drug
code
Controlled substance
Methylphenidate ............
Hydromorphone .............
Hydrocodone .................
Oripavine .......................
Thebaine ........................
Tapentadol .....................
1724
9150
9193
9330
9333
9780
Schedule
II
II
II
II
II
II
The company plans to manufacture
the above-listed controlled substances
in bulk for distribution to its customers.
No other activities for these drug codes
are authorized for this registration.
William T. McDermott,
Assistant Administrator.
[FR Doc. 2020–26651 Filed 12–2–20; 8:45 am]
BILLING CODE 4410–09–P
Suzanne Morris,
Chief, Premerger and Division Statistics,
Antitrust Division.
DEPARTMENT OF JUSTICE
[FR Doc. 2020–26626 Filed 12–2–20; 8:45 am]
Federal Bureau of Investigation
BILLING CODE 4410–11–P
[OMB Number 1110–0051]
DEPARTMENT OF JUSTICE
Agency Information Collection
Activities; Proposed eCollection
eComments Requested; Revision of a
Currently Approved Collection; Final
Disposition Report (R–84), With
Supplemental Questions R–84(a), R–
84(b), R–84(c), R–84(d), R–84(e), R–
84(f), R–84(g), R–84(h), R–84(i), and R–
84(j)
Drug Enforcement Administration
[Docket No. DEA–750]
Bulk Manufacturer of Controlled
Substances Application: Janssen
Pharmaceuticals Inc.
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Janssen Pharmaceuticals Inc.,
has applied to be registered as a bulk
manufacturer of basic class(es) of
controlled substance(s). Refer to
Supplemental Information listed below
for further drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before February 1, 2021. Such
persons may also file a written request
for a hearing on the application on or
before February 1, 2021.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152.
khammond on DSKJM1Z7X2PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
19:48 Dec 02, 2020
Jkt 253001
Criminal Justice Information
Services Division, Federal Bureau of
Investigation, Department of Justice.
ACTION: 30-day notice.
AGENCY:
The Criminal Justice
Information Services (CJIS) Division,
Federal Bureau of Investigation (FBI),
Department of Justice (DOJ), will be
submitting the following information
collection request to the Office of
Management and Budget (OMB) for
review and approval in accordance with
the Paperwork Reduction Act of 1995.
DATES: Comments are encouraged and
will be accepted for an additional 30
days until January 4, 2021.
ADDRESSES: Written comments and
recommendations for the proposed
information collection should be sent
within 30 days of publication of this
notice to www.reginfo.gov/public/do/
PRAMain. Find this particular
information collection by selecting
SUMMARY:
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
78149
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function.
SUPPLEMENTARY INFORMATION: Written
comments and suggestions from the
public and affected agencies concerning
the proposed collection of information
are encouraged. Your comments should
address one or more of the following
four points:
—Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
—Evaluate the accuracy of the agencies
estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
—Evaluate whether and if so how the
quality, utility, and clarity of the
information to be collected can be
enhanced; and
—Minimize the burden of the collection
of information on those who are to
respond, including through the use of
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms
of information technology, e.g.,
permitting electronic submission of
responses.
Overview of This Information
Collection
(1) Type of Information Collection:
Revision of a currently approved
collection.
(2) Title of the Form/Collection: Final
Disposition Report.
(3) Agency form number, if any, and
the applicable component of the
Department sponsoring the collection:
Agency form number: R–84, with
supplemental questions R–84(a), R–
84(b), R–84(c), R–84(d), R–84(e), R–
84(f), R–84(g), R–84(h), R–84(i), and R–
84(j).
Sponsoring component: Department
of Justice, Criminal Justice Information
Services Division.
(4) Affected public who will be asked
or required to respond, as well as a brief
abstract: Primary: City, county, state,
federal and tribal law enforcement
agencies. This collection is needed to
report completion of an arrest event.
Acceptable data is stored as part of the
Next Generation Identification (NGI)
system of the FBI.
(5) An estimate of the total number of
respondents and the amount of time
estimated for an average respondent to
respond/reply: It is estimated that
75,605 respondents will complete each
form within approximately 5 minutes.
E:\FR\FM\03DEN1.SGM
03DEN1
]]>Agencies
[Federal Register Volume 85, Number 233 (Thursday, December 3, 2020)]
[Notices]
[Pages 78148-78149]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-26626]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Antitrust Division
Notice Pursuant to the National Cooperative Research and
Production Act of 1993--Subcutaneous Drug Development & Delivery
Consortium, Inc.
Notice is hereby given that, on October 26, 2020, pursuant to
Section 6(a) of the National Cooperative Research and Production Act of
1993, 15 U.S.C. 4301 et seq. (``the Act''), Subcutaneous Drug
Development & Delivery Consortium, Inc. (``Subcutaneous Drug
Development & Delivery Consortium, Inc.'') has filed written
notifications simultaneously with the Attorney General and the Federal
Trade Commission disclosing (1) the identities of the parties to the
venture and (2) the nature and objectives of the venture. The
notifications were filed for the purpose of invoking the Act's
provisions limiting the recovery of antitrust plaintiffs to actual
damages under specified circumstances.
Pursuant to Section 6(b) of the Act, the identity of the parties to
the venture are: Eli Lilly and Company, Indianapolis, IN; Halozyme,
Inc., San Diego, CA; Bristol Myers Squibb, New Brunswick, NJ;
AstraZeneca, San Francisco, CA; and Amgen Inc., Thousand Oaks, CA. The
general area of Subcutaneous Drug Development & Delivery Consortium,
Inc.'s planned activity is (a) transform patient care and improve
patient outcomes by identifying and addressing key gaps, unmet needs
and actionable issues in the dynamic subcutaneous (``SC'') drug
delivery and development landscape, including through research,
publication of industry analyses, and the
[[Page 78149]]
development of SC-related manuscripts, models, standards and other
guidance materials (collectively, ``Guidance''); (b) provide a venue
for reviewing, developing, maintaining and supporting the Guidance; (c)
promote the Guidance worldwide; (d) provide for testing and conformity
assessment of implementations in order to ensure and/or facilitate
compliance with Guidance; (e) operate a branding program based upon
distinctive trademarks to create high customer awareness of, demand
for, and confidence in the Guidance, and products or services designed
in compliance therewith; and (f) undertake such other activities as may
from time to time be appropriate to further the purposes and achieve
the goals set forth above.
Membership in Subcutaneous Drug Development & Delivery Consortium,
Inc. remains open and Subcutaneous Drug Development & Delivery
Consortium, Inc. intends to file additional written notifications
disclosing all changes in membership.
Suzanne Morris,
Chief, Premerger and Division Statistics, Antitrust Division.
[FR Doc. 2020-26626 Filed 12-2-20; 8:45 am]
BILLING CODE 4410-11-P
